NRX Non Currrent Assets Other from 2010 to 2025
| NRXP Stock | USD 1.99 0.08 3.86% |
Non Currrent Assets Other | First Reported 2017-09-30 | Previous Quarter 384 K | Current Value 356 K | Quarterly Volatility 218.1 K |
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 372.8 K, Interest Expense of 131.1 K or Selling General Administrative of 20.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
NRX | Non Currrent Assets Other |
Latest NRX Pharmaceuticals' Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of NRX Pharmaceuticals over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. NRX Pharmaceuticals' Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRX Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
NRX Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | 93,475 | |
| Coefficient Of Variation | 218.37 | |
| Mean Deviation | 145,832 | |
| Median | 29,443 | |
| Standard Deviation | 204,120 | |
| Sample Variance | 41.7B | |
| Range | 754.5K | |
| R-Value | 0.59 | |
| Mean Square Error | 29.1B | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | 25,326 | |
| Total Sum of Squares | 625B |
NRX Non Currrent Assets Other History
About NRX Pharmaceuticals Financial Statements
NRX Pharmaceuticals shareholders use historical fundamental indicators, such as Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 495.6 K | 520.4 K |
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.